Synthesis, ChracterizationAnd In- Vitro Studies On 2-Chloroquinolin In Derivatives As Anti- Alzheimer Disease.
Main Article Content
Abstract
The synthesis, characterization and in-vitro studies on 2-chloroquinolin in derivatives have been screened and carried out by developing a QSAR model. Using such an approach one could predict the activities of newly designed compounds before a decision is being made whether these compounds should be really synthesized and tested. The data set used for the QSAR analyses contains 23 molecules belonging to acetyl cholinesterase inhibitors.About 20 novel compounds containing quinoline designed using CHEMDRAW software.Then the ten best docked compounds are selected for spectral data of the synthesized comopunds was obtained from IR, 1H NMR, 13C NMR, and mass spectroscopy,then the compounds are subjected to in-vitro MTT asssay for cell viability method.Amoung the tested compounds S9 and S11 were shown to be the most effective against the evaluated cell lines. Work is being done to advance the search for new cholinesterase inhibitors. In order to establish a SAR for rational study, more derivatives and in-depth, detailed investigations on in vivo activity may be undertaken. The current study suggests that more research is needed for quinoline derivatives developed as a potent lead for Anti- Alzheimer's disease.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Albert AA, Andrea C, Roberto N, Aydie H, Emidio C, Jordi M, Roberto P, Antonio M, “Exploring the effect of PARP-1 flexibility in docking studies”, Journal of Molecular Graphics and Modelling, 45, (2013): 192 –201
.Roko Z, Andreja M, Eva B, Ivan A, “Molecular Insights into Poly(ADP-ribose) Recognition and Processing:,Biomolecules, 3 (2013): 1- 17
Julio CM, Longshan L, Farjana JF, Ying D, Erik AB, Malina P, Jinming G, David AB, “Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases” Critical Reviews TM in Eukaryotic Gene Expression, 24 no. 1, (2014): 15 - 28.
Elizabeth Eldhose, Gowrmma B, Manal Mohammed, Kalirajan R, Kavarasan L, “Translational chemotherapy for triple negative breast cancer -A review on significance of poly (ADP-ribose) polymerase 1 (PARP1) inhibitors”. Research Journal of Pharmacy and Technology. 12 no. 6, (2019): 1-7.
Rupinder KS, Nirmal S, Amteshwar SJ, “Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications”. Vascular Pharmacology, 53, (2010): 77–87.
Kaviarasan L, Elizabeth E, Praveen TK, Kalirajan R, Manal M, Pulla Prudviraj and Gowramma B, “1,3,4-Thiadiazolo (3,2-Α) Pyrimidine-6-Carbonitrile Scaffold as PARP1 Inhibitor”, Anti-Cancer Agents in Medicinal Chemistry, 21, (2021): 1-16.
Hui L, Yan H, Xueyan W, Guangwei H, Yungen X, Qihua Z, “Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation”. Bioorganic & Medicinal Chemistry, 24, (2016): 4731–4740.
Kovi KE, Yearick K, Iwaniuk DP, Natarajan JK, Alumasa J, de Dois AC, Roepe PD, Wolf C, “Search for new pharmacophores for antimalarial activity. Part I: synthesis and antimalarial activity of new 2-methyl-6-ureido-4-quinolinamides” Bioorg. Med. Chem, 17, (2009): 270–283.
Snider DE, Raviglione M Jr, Kochi A. Global burden of tuberculosis, chapter 1. In: Tuberculosis:Pathogenisis, Protection, and Control. American society for Microbiology, Washington, DC 20005.1994:3–11.
El-Shorbagi AN, Chaudhary S, Alshemali KA, et al. A comprehensive review on management of Parkinson’s disease, inclusive of drug discovery and pharmacological approaches. J Appl Pharm Sci 2020; 10: 130–150.
Subramanian G, Chand J, Jupudi S, et al. Synthesis and Biological Evaluation of the Selected Naphthalene Substituted Azetidinone Derivatives Targeting Parkinson’s Disease. Indian J Pharm Educ Res 2023; 57: 552– 558.
Cheong SL, Federico S, Spalluto G, et al. The current status of pharmacotherapy for the treatment of Parkinson’s disease: transition from single-target to multitarget therapy. Drug Discov Today 2019; 24: 1769– 1783.
Zhang Y, Xu X. Chinese Herbal Medicine in the Treatment of Depression in Parkinson’s Disease: From Molecules to Systems. Front Pharmacol 2022; 13.
Dorszewska J, Kowalska M, Prendecki M, et al. Oxidative stress factors in Parkinson’s disease. Neural RegenRes 2021; 16: 1383–1391. doi:10.4103/1673-5374.300980
Sawa K, Uematsu T, Korenaga Y, et al. Krebs cycle intermediates protective against oxidative stress bymodulating the level of reactive oxygen species in neuronal HT22 cells. Antioxidants 2017; 6.
Shen Y, Wu Q, Shi J, et al. Regulation of SIRT3 on mitochondrial functions and oxidative stress in Parkinson’s disease. Biomed Pharmacother 2020; 132: 110928.
Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol Improves Mitochondrial Function and Protectsagainst Metabolic Disease by Activating SIRT1 and PGC-1α. Cell 2006; 127: 1109–1122.
Zhang B, Zhai M, Li B, et al. Honokiol ameliorates myocardial ischemia/reperfusion injury in type 1 diabeticrats by reducing oxidative stress and apoptosis through activating the SIRT1-Nrf2 signaling pathway. OxidMed Cell Longev 2018; 2018.
Baeken MW, Schwarz M, Kern A, et al. The selective degradation of sirtuins via macroautophagy in theMPP+ model of Parkinson’s disease is promoted by conserved oxidation sites. Cell Death Discov 2021; 7.
Zang H, Yang W, Tian X. Simvastatin in the Treatment of Colorectal Cancer : A Review. 2022.
Jia CY, Li JY, Hao GF, et al. A drug-likeness toolbox facilitates ADMET study in drug discovery. DrugDiscov Today 2020; 25: 248–258. doi:10.1016/j.drudis.2019.10.014
Zhang J, Xiang H, Liu J, et al. Mitochondrial Sirtuin 3: New emerging biological function and therapeutictarget. Theranostics 2020; 10: 8315–8342. doi:10.7150/thno.45922
Chen Y, Fu LL, Wen X, et al. Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressivefunction in cancer. Cell Death Dis 2014; 5: 1–7.
Lu J, Zhang H, Chen X, et al. A small molecule activator of SIRT3 promotes deacetylation and activation ofmanganese superoxide dismutase. Free Radic Biol Med 2017; 112: 287–297.
El Faydy M, Dahaieh N, Ounine K, et al. Synthesis, Identification, Antibacterial Activity, ADME/T and DNA-Docking Investigations of 8-Quinolinol Analogs Bearing a Benzimidazole Moiety. Arab J Sci Eng2022; 47: 497–510. doi:10.1007/s13369-021-05749-7
Hasan MM, Khan Z, Chowdhury MS, et al. In silico molecular docking and ADME/T analysis of Quercetincompound with its evaluation of broad-spectrum therapeutic potential against particular diseases. InformaticsMed Unlocked 2022; 29: 100894. doi:10.1016/j.imu.2022.100894
Ajiboye BO, Fagbola TM, Folorunso IM, et al. In silico identification of chemical compounds in Spondiasmombin targeting aldose reductase and glycogen synthase kinase 3β to abate diabetes mellitus. InformaticsMed Unlocked 2023; 36: 101126.
Ahmad F. Ganoderic Acid A targeting leucine-rich repeat kinase 2 involved in Parkinson’s disease–Acomputational study. Aging Med 2023; 6: 272–280.
Ranade SD, Alegaon SG, Venkatasubramanian U, et al. Design, synthesis, molecular dynamics simulation,MM/GBSA studies and kinesin spindle protein inhibitory evaluation of some 4-aminoquinoline hybrids.Comput Biol Chem 2023; 105: 107881.
Synthesis of novel quinoline-based thiadiazole, evaluation of their antileishmanialpotential and molecular docking studies – ScienceDirecthttps://www.sciencedirect.com/science/article/abs/pii/S0045206818301044 (accessed2021 -12 -26).
A. Atri, L. Frölich, C. Ballard, PN. Tariot, JL. Molinuevo, N. Boneva, K. Windfeld, LL. Raket, and JL. Cummings. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients with Alzheimer Disease: Three Randomized Clinical Trials. JAMA, 2018; 319: 130–142.